3 completed, 3 recruiting, 2 withdrawn, 1 active not recruiting. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 3, Recruiting 3, Withdrawn 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
Follow Palbociclib 125mg: new trials by email Literature Review of Palbociclib 125mg trials Research Report on Palbociclib 125mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet - Metastatic Breast Cancer, Breast Cancer Stage I | Phase 1 / Phase 2 | Recruiting | Forward Pharmaceuticals Co., Ltd. | 196 | 2025-06-01 | 2026-01-07 |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy Palbociclib 125mg - Breast Cancer | Phase 2 | Active not recruiting | University of Nebraska | 51 | 2022-03-02 | 2026-10-09 |
| Combined Immunotherapies in Metastatic ER+ Breast Cancer Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions), Letrozole 2.5Mg Tab, Palbociclib 125mg - Breast Cancer | Phase 2 | Recruiting | Weill Medical College of Cornell University | 102 | 2020-11-12 | 2025-12-15 |
| PLATFORM Study of Precision Medicine for Rare Tumors Almonertinib 110 MG, Dacomitinib 45 MG, Alectinib 150 MG - Rare Tumor | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 770 | 2020-08-15 | 2025-02-11 |
| Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer Palbociclib 125mg, Letrozole 2.5mg - Ovarian Cancer | Phase 2 | Completed | Latin American Cooperative Oncology Group | 43 | 2020-03-05 | 2024-02-20 |
| CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions), Letrozole 2.5Mg Tab, Palbociclib 125mg - Breast Cancer | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2020-03-04 | 2020-09-21 | |
| Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Palbociclib 75mg, Letrozole 2.5mg, T-DM1 - HER2-positive Breast Cancer, Breast Cancer Metastatic | Phase 1 / Phase 2 | Terminated | University of Kansas Medical Center | 3 | 2018-10-15 | 2024-03-05 |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer Palbociclib 125mg - Cancer, Advanced | Phase 2 | Withdrawn | Razelle Kurzrock, MD | 2018-07-01 | 2018-06-21 | |
| Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer Palbociclib 100mg, Palbociclib 125mg, Fulvestrant or Tamoxifen or Aromatase Inhibitor - Breast Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 180 | 2016-04-08 | 2026-04-13 |
| PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Palbociclib 200mg, Palbociclib 125mg - Sarcoma, Liposarcoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 90 | 2010-09-23 | 2017-11-06 |
Breast Neoplasms (5) · Liposarcoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Sarcoma (1)
Weill Medical College of Cornell University (2) · Canadian Cancer Trials Group (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Forward Pharmaceuticals Co., Ltd. (1) · Latin American Cooperative Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · Razelle Kurzrock, MD (1) · University of Kansas Medical Center (1) · University of Nebraska (1)
United States (5) · China (2) · Brazil (1) · Canada (1)
Silvia Formenti, M.D. (2) · Amulya Yellala, MBBS (1) · Anil A. Joy (1) · Fernanda Bronzon Damian (1) · Lauren Nye, MD (1) · Mark Dickson, MD (1) · Ning Li, Doctor (1) · Scott Lippman, MD (1)
PMID 23569312, PMID 27124835, PMID 32641862, PMID 34083331, PMID 41123599